- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01454973
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78209
- ICON Development Solutions, Gault Lane
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Ability to give informed consent and comply with all study requirements
- Overweight and obese, generally healthy men and women. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.
Women of child-bearing potential are allowed (but must agree to use non-hormonal contraception and not plan to become pregnant for the duration of the study. Must agree to maintain the same contraceptive measures throughout the study. Acceptable contraceptive methods for female subjects of childbearing potential include one of the following:
- Abstinence.
One (1) of the following methods:
- Tubal ligation
- Copper-containing intrauterine device (IUD)
- Condom AND spermicidal foam/gel/film/cream/suppository
- Male partner who has had a vasectomy for at least 6 months.
It is required that all male subjects use an acceptable method of contraception (as outlined below), starting from the first dose of study medication and continuing for at least 28 days after the last dose of study drug:
- Abstinence
- A condom AND one of the following:
- Vasectomy for more than 6 months. Female partner who meets one of the following conditions: has had a tubal ligation, hysterectomy, or bilateral oophorectomy; or is post menopausal
- BMI 27-40; stable weight (less than 3% change in past 3 months) Age Range: 30-65
- No history of diabetes mellitus or impaired glucose tolerance (and impaired fasting glucose)
- Other conditions may be allowed, if medically stable and controlled within acceptable limits, including: hypertension, dyslipidemia, osteoarthritis, osteoporosis
- Smokers allowed, but must be able to participate on inpatient stay and not smoke
- Normal oral glucose tolerance test response (see exclusion criteria)
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the study:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic or clinical findings at Screening.
- Any condition possibly affecting absorption (eg, gastrectomy, malabsorption syndromes, abdominal surgery other than appendectomy, cholecystectomy or hysterectomy).
- Use of unacceptable medications (see Appendix A)
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
- Treatment with an investigational drug within 30 days or 5 half-lives preceding the first dose of study medication.
- 12 lead ECG demonstrating QTc >450 msec at Screening for males, 470 msec for females. If QTc exceeds 450/470 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
- Supine blood pressure >=140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single measurement. If elevated, confirm by a single repeat, following at least 10 minutes of rest.
- Screening fasting serum glucose >=100 mg/dL or HbA1c >6.5%, confirmed by a single repeat if deemed necessary.
- Abnormal oral glucose tolerance test (see below for definition of abnormal).
- Screening serum alanine transaminase (ALT) or serum aspartate transaminase (AST) greater than 2X the upper limit of the laboratory reference range.
- Elevated fasting triglycerides at screening (>500 mg/dL), confirmed by a single repeat if deemed necessary.
- Pregnant or nursing females; inability to use effective contraception.
- Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
- Participation in a clinical biomedical research study within prior two months may be excluded, depending on study type and details.
- History of sensitivity to heparin or heparin-induced thrombocytopenia, if utilized by the site for blood draws.
- Unwilling or unable to comply with directions and procedures described in this protocol.
- Subject is the Investigator or a sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or a relative of study personnel directly involved with the conduct of the study.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Healthy obese individuals
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: George Atiee, M.D., ICON Development Solutions
Publicaciones y enlaces útiles
Publicaciones Generales
- Ruetten H, Gebauer M, Raymond RH, Calle RA, Cobelli C, Ghosh A, Robertson RP, Shankar SS, Staten MA, Stefanovski D, Vella A, Wright K, Fryburg DA; Foundation for the NIH Biomarkers Consortium Beta Cell Project Team. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with beta Cell Function. Metab Syndr Relat Disord. 2018 Oct;16(8):406-415. doi: 10.1089/met.2018.0022. Epub 2018 Aug 17. Erratum In: Metab Syndr Relat Disord. 2019 Mar;17(2):128.
- Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA; Foundation for the National Institutes of Health beta-Cell Project Team. Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of beta-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care. 2016 Sep;39(9):1602-13. doi: 10.2337/dc15-0931. Epub 2016 Jul 12.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Beta Cell - Protocol 1a
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes tipo 2
-
Jin-Hee AhnAsan Medical CenterDesconocidoAmplificación del gen HER-2 | Sobreexpresión de proteína HER-2
-
The University of Tennessee, KnoxvilleTerminadoProfesores de Matemáticas (Grados 2-8) | Estudiantes de Matemáticas (Grados 2-8)Estados Unidos
-
PowderMedTerminado
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.DesconocidoTumor solido | Amplificación del gen HER-2 | Mutación del gen HER2 | Sobreexpresión de proteína HER-2Porcelana
-
Argorna Pharmaceuticals Co., LTDTerminado
-
Argorna Pharmaceuticals Co., LTDTerminado
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Activo, no reclutando
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical...Activo, no reclutando
-
Arcturus Therapeutics, Inc.Terminado
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsTerminado